TapImmune appoints David Laskow-Pooley to board
This article was originally published in Scrip
TapImmune, an immunotherapy company specializing in the development of therapies for cancer and infectious disease, has appointed David Laskow-Pooley to its board of directors. Mr Laskow-Pooley is currently CEO of London Pharma, a clinical-stage company re-purposing approved drugs through novel drug delivery technologies, and is the co-founder of Pharmafor. He was formerly managing director (UK) of Nasdaq-listed drug discovery platform company, OSI, and was part of the corporate team that developed and launched Tarceva for the treatment of lung cancer with marketing partners Roche and Genentech.
You may also be interested in...
In the latest instalment of our VC playbook series, In Vivo sits down with Roel Bulthuis, managing partner at INKEF Capital, to discuss the group’s approach to health care investing in Europe, the importance of funding a team not just a project and how life sciences venture capital is evolving with the emergence of health tech.
Our readers have been voting and the results have been counted. The winners of In Vivo's annual Deals Of The Year contest are ...
It is time for In Vivo's 12th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.